T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward (Q36830388)

16 August 2017

T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward (English)

1 reference

16 August 2017

0 references

1 reference

1 reference

Madhukar Pai

1

0 references

Keertan Dheda

series ordinal

2

object named as

Keertan Dheda

1 reference

16 August 2017

Jane Cunningham

3

1 reference

PubMed ID

17521596

16 August 2017

Fabio Scano

series ordinal

4

1 reference

PubMed ID

17521596

16 August 2017

Richard O'Brien

series ordinal

5

1 reference

16 August 2017

1 June 2007

1 reference

Lancet Infectious Diseases

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

6

1 reference

16 August 2017

428-438

1 reference

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

The tuberculin skin test

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Specific immune-based diagnosis of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Diagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Interferon-gamma assays -- description and assessment of a new tool in the diagnosis of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Advances in the diagnosis and treatment of tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

The diagnosis of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Interferon-gamma release assays for diagnosis of tuberculosis infection in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

QuantiFERON-TB Gold: state of the art for the diagnosis of tuberculosis infection?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Counting Antigen‐Specific T Cells: A New Approach for Monitoring Response to Tuberculosis Treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Use of enzyme-linked immunospot assay with Mycobacterium tuberculosis-specific peptides for diagnosis of recent infection with M. tuberculosis after accidental laboratory exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Long-lived immune response to early secretory antigenic target 6 in individuals who had recovered from tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Sensitivity of a whole-blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during anti-tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

1 reference

7 January 2021

Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

1 reference

7 January 2021

Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T-SPOT.TB test, tuberculin skin test, and an expert physician panel

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Comparison of a whole blood interferon-gamma assay with tuberculin skin testing for the detection of tuberculosis infection in hospitalized children in rural India.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Enzyme-Linked Immunospot Assay Responses to Early Secretory Antigenic Target 6, Culture Filtrate Protein 10, and Purified Protein Derivative among Children with Tuberculosis: Implications for Diagnosis and Monitoring of Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Risk for tuberculosis among children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

The negative tuberculin test. Tuberculin, HIV, and anergy panels

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Interferon-γ Assays for Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Childhood pulmonary tuberculosis: old wisdom and new challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Tuberculosis in children: considerations for children from developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

The prognosis of a positive tuberculin reaction in childhood and adolescence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Annual risk of infection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Estimation of test error rates, disease prevalence and relative risk from misclassified data: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Tuberculosis among health-care workers in low- and middle-income countries: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Serial testing of health care workers for tuberculosis using interferon-gamma assay

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Dynamic Antigen-specific T-Cell Responses after Point-Source Exposure toMycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Here today--gone tomorrow: the case for transient acute tuberculosis infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Guidelines for conducting tuberculin skin test surveys in high prevalence countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Mycobacterium tuberculosis Infection in Health Care Workers in Rural India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

ESAT-6 and CFP-10 in clinical versus environmental isolates of Mycobacterium kansasii

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Identification and characterization of the ESAT-6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Immunological crossreactivity of the Mycobacterium leprae CFP-10 with its homologue in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Cost-optimisation of screening for latent tuberculosis in close contacts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Direct costs of three models for the screening of latent tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Priorities for the Treatment of Latent Tuberculosis Infection in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Cost effectiveness analysis of strategies for tuberculosis control in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Progress towards improved tuberculosis diagnostics for developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Partnering for better microbial diagnostics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

WHO's new Stop TB Strategy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

Reducing the global burden of tuberculosis: the contribution of improved diagnostics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970086-5

7 January 2021

10.1016/S1473-3099(07)70086-5

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17521596